• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
By BRET JENSEN
Apr 11, 2018 | 01:00 PM EDT
Stocks quotes in this article: NVS, AVXS, BLUE, CELG, JUNO, EDIT, GILD, KITE, CLVS, AZN, TSRO, NEOS

One thing I am hoping to see during the second quarter is increased M&A activity in the biotech space. Deal volume was strong in January thanks partly to clarity provided by tax reform and more importantly the need for major drug and pharma giants to replenish their pipelines. However, transactions dried up in February and March after volatility spiked in the market. The VIX or "fear index" is now up some 70% from where it began the year.

A good sign on that front came Monday morning with Novartis (NVS) announcing it will buy AveXis (AVXS) for $8.7 billion after it raised some $13 billion by selling its stake in a consumer healthcare joint venture. This is a huge win for AveXis' shareholders as the buyout price is more than 80% above where the stock closed on Friday.

This has ignited a rally in other gene therapy concerns. One of these is Bluebird Bio (BLUE) , which I would fade. The company has a huge collaboration deal with Celgene (CELG) . This makes it an unlikely purchase unless it is by that biotech stalwart, which is still digesting its recent acquisition of Juno Therapeutics (JUNO) . Gene-editing concerns such as Editas Medicine (EDIT) are more likely acquisitions, in my opinion, and that particular one has been speculatively linked to Gilead Sciences (GILD) in the past. Gilead made its own foray into this space recently with its $12 billion purchase of Kite Pharma (KITE) in August of last year.

I believe that the oncology space will continue to see a good share of new deals at nice premiums. One name I like as a standalone pick as well as a potential buyout target is Clovis Oncology (CLVS) . During the carnage last Friday in the market, the FDA granted its lead drug "Rubraca" a label expansion for second-line or later maintenance treatment in patients with the cancer. Importantly, the extension came with a "clean label." Rubraca will compete in this indication against Lynparza from AstraZeneca (AZN) which has a label warning for pneumonitis as well as Zeluja from Tesaro (TSRO) which warns for blood toxicity and cardiovascular events. This removes an overhang from Rubraca's investment case and should help ramp up sales significantly (the drug did $55 million in sales in 2017, its first year on the market).

Outside of oncology, I think Neos Therapeutics (NEOS) which already has rebuffed one hostile low-ball bid, makes sense as an acquisition target. It has had three drugs to treat ADHD (attention-deficit/hyperactivity disorder)  approved over the past 18 months and sales are ramping impressively. The ADHD space is a $10 billion market with several competitors. Even with a solid buyout premium this would be less than a $400 million purchase, which is a "bite-sized" deal. I also think the management team is more than willing to be acquired at the right price.

Those are several names I like if the "animal spirits" in M&A pick up in the months ahead, which I think is likely.

This commentary originally appeared on our sister site Real Money Pro on April 9. Click here to learn about this dynamic market information service for active traders and to receive daily columns from Jensen, Ed Ponsi, Paul Price and others.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long CELG, CLVS, GILD and NEOS.

TAGS: Investing | U.S. Equity | Healthcare | Mergers and Acquisitions | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An interesting chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login